Sankyo's Antihypertensive Agent, ARB Olmesartan to Be Available in Central and South America.
Tokyo, Japan, Aug 8, 2005 - (JCNN) - Sankyo announced on August 5 that it has signed a licensing agreement with Schering-Plough for its proprietary antihypertensive agent, olmesartan, an angiotensin II receptor blocker.Under the terms of the agreement, Schering-Plough will exclusively sell the agent in Argentina, Boilvia, Chile, Paraguay, Peru and Uruguay.
In addition, Sankyo will allow Schering-Plough to co-market the agent in Costa Rica, the Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama and Venezuela.
Olmesartan is currently marketed in about 30 countries around the world.
Source: JCN http://www.japancorp.net
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
 Printer friendly
 Cite/link
 Email
 Feedback
| |
| Publication: | JCNN News Summaries |
|---|---|
| Geographic Code: | 1USA |
| Date: | Aug 9, 2005 |
| Words: | 103 |
| Previous Article: | Ivy Cosmetics, Kitasato University Jointly Confirm That Shellac May Combat Skin Disorders. |
| Next Article: | Nippon Organon to Release Recombinant Follicle Stimulating Hormone Follistim. |
| Topics: | |